AMITRIPTYLINE HYDROCHLORIDE tablet, film coated

United States - English - NLM (National Library of Medicine)

Buy It Now

Active ingredient:
AMITRIPTYLINE HYDROCHLORIDE (UNII: 26LUD4JO9K) (AMITRIPTYLINE - UNII:1806D8D52K)
Available from:
Bryant Ranch Prepack
Administration route:
ORAL
Prescription type:
PRESCRIPTION DRUG
Therapeutic indications:
For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than are other depressive states. Amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. It should not be given concomitantly with monoamine oxidase inhibitors. Hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. When it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. Amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. Amitriptyline hydrochloride should not be given with cisapride due to the potential for increased QT interval and increased risk for arrhythmia. This drug is not recommended for use during the acute recovery phase following myocardial infarc
Product summary:
Product: 71335-1254 NDC: 71335-1254-0 120 TABLET, FILM COATED in a BOTTLE NDC: 71335-1254-1 20 TABLET, FILM COATED in a BOTTLE NDC: 71335-1254-2 30 TABLET, FILM COATED in a BOTTLE NDC: 71335-1254-3 100 TABLET, FILM COATED in a BOTTLE NDC: 71335-1254-4 60 TABLET, FILM COATED in a BOTTLE NDC: 71335-1254-5 50 TABLET, FILM COATED in a BOTTLE NDC: 71335-1254-6 90 TABLET, FILM COATED in a BOTTLE NDC: 71335-1254-7 45 TABLET, FILM COATED in a BOTTLE NDC: 71335-1254-8 28 TABLET, FILM COATED in a BOTTLE NDC: 71335-1254-9 56 TABLET, FILM COATED in a BOTTLE Product: 71335-1256 NDC: 71335-1256-1 100 TABLET, FILM COATED in a BOTTLE NDC: 71335-1256-2 30 TABLET, FILM COATED in a BOTTLE NDC: 71335-1256-3 60 TABLET, FILM COATED in a BOTTLE NDC: 71335-1256-4 90 TABLET, FILM COATED in a BOTTLE NDC: 71335-1256-5 20 TABLET, FILM COATED in a BOTTLE NDC: 71335-1256-6 28 TABLET, FILM COATED in a BOTTLE NDC: 71335-1256-7 56 TABLET, FILM COATED in a BOTTLE NDC: 71335-1256-8 180 TABLET, FILM COATED in a BOTTLE
Authorization status:
Abbreviated New Drug Application
Authorization number:
71335-1254-0, 71335-1254-1, 71335-1254-2, 71335-1254-3, 71335-1254-4, 71335-1254-5, 71335-1254-6, 71335-1254-7, 71335-1254-8, 71335-1254-9, 71335-1256-1, 71335-1256-2, 71335-1256-3, 71335-1256-4, 71335-1256-5, 71335-1256-6, 71335-1256-7, 71335-1256-8

AMITRIPTYLINE HYDROCHLORIDE- amitriptyline hydrochloride tablet, film coated

Bryant Ranch Prepack

----------

MEDICATION GUIDE

Amitriptyline Hydrochloride Tablets, USP

(am'' i trip' ti leen hye'' droe klor' ide)

Antidepressant Medicines, Depression and other Serious Mental Illnesses, and Suicidal Thoughts or Actions

Read the Medication Guide that comes with you or your family member's antidepressant medicine. This

Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines.

Talk to your, or your family member's, healthcare provider about:

all risks and benefits of treatment with antidepressant medicines

all treatment choices for depression or other serious mental illness

What is the most important information I should know about antidepressant medicines, depression and other

serious mental illnesses, and suicidal thoughts or actions?

Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and

young adults within the first few months of treatment.

Depression and other serious mental illnesses are the most important causes of suicidal thoughts and

actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These

include people who have (or have a family history of) bipolar illness (also called manic-depressive

illness) or suicidal thoughts or actions.

How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?

Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or

feelings. This is very important when an antidepressant medicine is started or when the dose is

changed.

Call the healthcare provider right away to report new or sudden changes in mood, behavior,

thoughts, or feelings.

Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider

between visits as needed, especially if you have concerns about symptoms.

Call a healthcare provider right away if you or your family member has any of the following

symptoms, especially if they are new, worse, or worry you:

thoughts about suicide or dying

attempts to commit suicide

new or worse depression

new or worse anxiety

feeling very agitated or restless

panic attacks

trouble sleeping (insomnia)

new or worse irritability

acting aggressive, being angry, or violent

acting on dangerous impulses

an extreme increase in activity and talking (mania)

other unusual changes in behavior or mood

Visual problems: eye pain, changes in vision, swelling or redness in or around the eye

What else do I need to know about antidepressant medicines?

Never stop an antidepressant medicine without first talking to a healthcare provider. Stopping an

antidepressant medicine suddenly can cause other symptoms.

Visual problems: Only some people are at risk for these problems. You may want to undergo an eye

examination to see if you are at risk and receive preventative treatment if you are.

Antidepressants are medicines used to treat depression and other illnesses. It is important to discuss all

the risks of treating depression and also the risks of not treating it. Patients and their families or other

caregivers should discuss all treatment choices with the healthcare provider, not just the use of

antidepressants.

Antidepressant medicines have other side effects. Talk to the healthcare provider about the side effects

of the medicine prescribed for you or your family member.

Antidepressant medicines can interact with other medicines. Know all of the medicines that you or your

family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new

medicines without first checking with your healthcare provider.

Not all antidepressant medicines prescribed for children are FDA approved for use in children. Talk to

your child's healthcare provider for more information.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-

1088.

This Medication Guide has been approved by the U.S. Food and Drug Administration for all antidepressants.

Distributed by:

Sun Pharmaceutical Industries, Inc.

Cranbury, NJ 08512

Rev 04, February 2018

Revised: 8/2019

Document Id: 8bd854ea-cc6e-43d6-bbd8-af8f43460c45

34391-3

Set id: 541ba74a-babb-4731-a5ef-fe7c18992c0b

Version: 2

Effective Time: 20190813

Bryant Ranch Prepack

AMITRIPTYLINE HYDROCHLORIDE- amitriptyline hydrochloride tablet, film coated

Bryant Ranch Prepack

----------

AMITRIPTYLINE HYDROCHLORIDE TABLETS USP

Rx only

Suicidality and Antidepressant Drugs:

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior

(suicidality) in children, adolescents, and young adults in short-term studies of major

depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of

amitriptyline hydrochloride or any other antidepressant in a child, adolescent, or young

adult must balance this risk with the clinical need. Short-term studies did not show an

increase in the risk of suicidality with antidepressants compared to placebo in adults

beyond age 24; there was a reduction in risk with antidepressants compared to placebo in

adults aged 65 and older. Depression and certain other psychiatric disorders are

themselves associated with increases in the risk of suicide. Patients of all ages who are

started on antidepressant therapy should be monitored appropriately and observed closely

for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers

should be advised of the need for close observation and communication with the prescriber.

Amitriptyline hydrochloride is not approved for use in pediatric patients. (See WARNINGS:

Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and

PRECAUTIONS: Pediatric Use).

DESCRIPTION

Amitriptyline HCl is 3-(10,11-dihydro-5H-dibenzo [a,d] cycloheptene-5-ylidene)-N,N-dimethyl-1-

propanamine hydrochloride. Its molecular formula is C

H N · HCl and its structural formula is:

Amitriptyline HCl, a dibenzocycloheptadiene derivative, has a molecular weight of 313.87. It is a white,

odorless, crystalline compound which is freely soluble in water.

Each tablet, for oral administration, contains 10 mg, 25 mg, 50 mg, 75 mg, 100 mg or 150 mg of

amitriptyline hydrochloride. In addition, each tablet contains the following inactive ingredients:

colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate,

microcrystalline cellulose, polyvinyl alcohol, talc, polyethylene glycol, and titanium dioxide; 10 mg

contains D&C Red No. 27 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, and FD&C Blue No.

1 Aluminum Lake; 25 mg contains D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 1 Aluminum

Lake, and FD&C Red No. 40 Aluminum Lake; 50 mg contains FD&C Yellow No. 5 Aluminum Lake,

FD&C Blue No. 2 Aluminum Lake, and FD&C Red No. 40 Aluminum Lake; 75 mg contains D&C Red

No. 7 Lake, and FD&C Blue No. 1 Aluminum Lake; 100 mg and 150 mg contain D&C Red No. 30 Lake,

and D&C Yellow No. 10 Aluminum Lake.

CLINICAL PHARMACOLOGY

Amitriptyline HCl is an antidepressant with sedative effects. Its mechanism of action in man is not

known. It is not a monoamine oxidase inhibitor and it does not act primarily by stimulation of the central

nervous system.

Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and

serotonin in adrenergic and serotonergic neurons. Pharmacologically this action may potentiate or

prolong neuronal activity since reuptake of these biogenic amines is important physiologically in

terminating transmitting activity. This interference with the reuptake of norepinephrine and/or serotonin

is believed by some to underlie the antidepressant activity of amitriptyline.

INDICATIONS AND USAGE

For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than

are other depressive states.

CONTRAINDICATIONS

Amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it.

It should not be given concomitantly with monoamine oxidase inhibitors. Hyperpyretic crises, severe

convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine

oxidase inhibiting drugs simultaneously. When it is desired to replace a monoamine oxidase inhibitor

with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is

discontinued. Amitriptyline hydrochloride should then be initiated cautiously with gradual increase in

dosage until optimum response is achieved.

Amitriptyline hydrochloride should not be given with cisapride due to the potential for increased QT

interval and increased risk for arrhythmia.

This drug is not recommended for use during the acute recovery phase following myocardial

infarction.

WARNINGS

Clinical Worsening and Suicide Risk

Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of

their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes

in behavior, whether or not they are taking antidepressant medications, and this risk may persist until

significant remission occurs. Suicide is a known risk of depression and certain other psychiatric

disorders, and these disorders themselves are the strongest predictors of suicide. There has been a

long-standing concern, however, that antidepressants may have a role in inducing worsening of

depression and the emergence of suicidality in certain patients during the early phases of treatment.

Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others)

showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children,

adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other

psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with

antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants

compared to placebo in adults aged 65 and older.

The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive

compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9

antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults

with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2

months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of

suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs

studied. There were differences in absolute risk of suicidality across the different indications, with the

highest incidence in MDD. The risk differences (drug vs placebo), however, were relatively stable

within age strata and across indications. These risk differences (drug-placebo difference in the number

of cases of suicidality per 1000 patients treated) are provided in Table 1.

Table 1

Age Range Drug-Placebo Difference in Number of Cases of Suicidality

per 1000 Patients Treated

Increases Compared to Placebo

<18

14 additional cases

18–24

5 additional cases

Decreases Compared to Placebo

25–64

1 fewer case

≥65

6 fewer cases

No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the

number was not sufficient to reach any conclusion about drug effect on suicide.

It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months.

However, there is substantial evidence from placebo-controlled maintenance trials in adults with

depression that the use of antidepressants can delay the recurrence of depression.

All patients being treated with antidepressants for any indication should be monitored

appropriately and observed closely for clinical worsening, suicidality, and unusual changes in

behavior, especially during the initial few months of a course of drug therapy, or at times of dose

changes, either increases or decreases.

The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility,

aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been

reported in adult and pediatric patients being treated with antidepressants for major depressive disorder

as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the

emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal

impulses has not been established, there is concern that such symptoms may represent precursors to

emerging suicidality.

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing

the medication, in patients whose depression is persistently worse, or who are experiencing emergent

suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if

these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

Families and caregivers of patients being treated with antidepressants for major depressive

disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the

need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior,

and the other symptoms described above, as well as the emergence of suicidality, and to report

such symptoms immediately to health care providers. Such monitoring should include daily

observation by families and caregivers. Prescriptions for amitriptyline hydrochloride tablets should

be written for the smallest quantity of tablets consistent with good patient management, in order to

reduce the risk of overdose.

Screening Patients for Bipolar Disorder

A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed

(though not established in controlled trials) that treating such an episode with an antidepressant alone

may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar

disorder. Whether any of the symptoms described above represent such a conversion is unknown.

However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should

be adequately screened to determine if they are at risk for bipolar disorder; such screening should

include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and

depression. It should be noted that amitriptyline hydrochloride is not approved for use in treating

bipolar depression.

Amitriptyline hydrochloride may block the antihypertensive action of guanethidine or similarly acting

compounds.

It should be used with caution in patients with a history of seizures and, because of its atropine-like

action, in patients with a history of urinary retention, angle-closure glaucoma or increased intraocular

pressure. In patients with angle-closure glaucoma, even average doses may precipitate an attack.

Patients with cardiovascular disorders should be watched closely. Tricyclic antidepressant drugs,

including amitriptyline hydrochloride, particularly when given in high doses, have been reported to

produce arrhythmias, sinus tachycardia, and prolongation of the conduction time. Myocardial infarction

and stroke have been reported with drugs of this class.

Close supervision is required when amitriptyline hydrochloride is given to hyperthyroid patients or

those receiving thyroid medication.

Amitriptyline hydrochloride may enhance the response to alcohol and the effects of barbiturates and

other CNS depressants. In patients who may use alcohol excessively, it should be borne in mind that the

potentiation may increase the danger inherent in any suicide attempt or overdosage. Delirium has been

reported with concurrent administration of amitriptyline and disulfiram.

Angle-Closure Glaucoma

The pupillary dilation that occurs following use of many antidepressant drugs including amitriptyline

hydrochloride may trigger an angle-closure attack in a patient with anatomically narrow angles who

does not have a patent iridectomy.

Usage in Pregnancy

Pregnancy Category C

Teratogenic effects were not observed in mice, rats, or rabbits when amitriptyline was given orally at

doses of 2 to 40 mg/kg/day (up to 13 times the maximum recommended human dose ). Studies in

literature have shown amitriptyline to be teratogenic in mice and hamsters when given by various routes

of administration at doses of 28 to 100 mg/kg/day (9 to 33 times the maximum recommended human

dose), producing multiple malformations. Another study in the rat reported that an oral dose of 25

mg/kg/day (8 times the maximum recommended human dose) produced delays in ossification of fetal

vertebral bodies without other signs of embryotoxicity. In rabbits, an oral dose of 60 mg/kg/day (20

times the maximum recommended human dose) was reported to cause incomplete ossification of the

cranial bones.

Amitriptyline has been shown to cross the placenta. Although a causal relationship has not been

established, there have been a few reports of adverse events, including CNS effects, limb deformities,

or developmental delay, in infants whose mothers had taken amitriptyline during pregnancy.

There are no adequate and well-controlled studies in pregnant women. Amitriptyline hydrochloride

should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to

the fetus.

Based on a maximum recommended amitriptyline dose of 150 mg/day or 3 mg/kg/day for a 50 kg patient.

Nursing Mothers

Amitriptyline is excreted into breast milk. In one report in which a patient received amitriptyline 100

mg/day while nursing her infant, levels of 83 to 141 ng/mL were detected in the mother's serum. Levels

of 135 to 151 ng/mL were found in the breast milk, but no trace of the drug could be detected in the

infant's serum.

Because of the potential for serious adverse reactions in nursing infants from amitriptyline, a decision

should be made whether to discontinue nursing or to discontinue the drug, taking into account the

importance of the drug to the mother.

Usage in Pediatric Patients

In view of the lack of experience with the use of this drug in pediatric patients, it is not recommended at

the present time for patients under 12 years of age.

PRECAUTIONS

Schizophrenic patients may develop increased symptoms of psychosis; patients with paranoid

symptomatology may have an exaggeration of such symptoms. Depressed patients, particularly those

with known manic-depressive illness, may experience a shift to mania or hypomania. In these

circumstances the dose of amitriptyline may be reduced or a major tranquilizer such as perphenazine

may be administered concurrently.

The possibility of suicide in depressed patients remains until significant remission occurs. Potentially

suicidal patients should not have access to large quantities of this drug. Prescriptions should be written

for the smallest amount feasible.

Concurrent administration of amitriptyline hydrochloride and electroshock therapy may increase the

hazards associated with such therapy. Such treatment should be limited to patients for whom it is

essential.

When possible, the drug should be discontinued several days before elective surgery.

Both elevation and lowering of blood sugar levels have been reported.

Amitriptyline hydrochloride should be used with caution in patients with impaired liver function.

This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions

(including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C

Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients

who also have aspirin hypersensitivity.

Information for Patients

Prescribers or other health professionals should inform patients, their families, and their caregivers

about the benefits and risks associated with treatment with amitriptyline hydrochloride and should

counsel them in its appropriate use. A patient Medication Guide about "Antidepressant Medicines,

Depression and other Serious Mental Illnesses, and Suicidal Thoughts or Actions" is available for

amitriptyline hydrochloride. The prescriber or health professional should instruct patients, their

families, and their caregivers to read the Medication Guide and should assist them in understanding its

contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to

obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted

at the end of this document.

Patients should be advised of the following issues and asked to alert their prescriber if these occur

while taking amitriptyline hydrochloride.

Patients should be advised that taking amitriptyline hydrochloride can cause mild pupillary dilation,

which in susceptible individuals, can lead to an episode of angle-closure glaucoma. Pre-existing

glaucoma is almost always open-angle glaucoma because angle-closure glaucoma, when diagnosed, can

be treated definitively with iridectomy. Open-angle glaucoma is not a risk factor for angle-closure

glaucoma. Patients may wish to be examined to determine whether they are susceptible to angle-closure,

and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.

Clinical Worsening and Suicide Risk

Patients, their families, and their caregivers should be encouraged to be alert to the emergence of

anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia

(psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of

depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is

adjusted up or down. Families and caregivers of patients should be advised to look for the emergence

of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be

reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset,

or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an

increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and

possibly changes in the medication.

While on therapy with amitriptyline hydrochloride, patients should be advised as to the possible

impairment of mental and/or physical abilities required for performance of hazardous tasks, such as

operating machinery or driving a motor vehicle.

Drug Interactions

Topiramate

Some patients may experience a large increase in amitriptyline concentration in the presence of

topiramate and any adjustments in amitriptyline dose should be made according to the patient's clinical

response and not on the basis of plasma levels.

Drugs Metabolized by P450 2D6

The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin

hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of Caucasians are so

called "poor metabolizers"), reliable estimates of the prevalence of reduced P450 2D6 isozyme activity

among Asian, African and other populations are not yet available. Poor metabolizers have higher than

expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending

on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or

quite large (8 fold increase in plasma AUC of the TCA).

In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble

poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic

when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome

P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are

substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics

propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g.,

fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The

extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of

inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the

coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of

particular importance, sufficient time must elapse before initiating TCA treatment in a patient being

withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks

may be necessary).

Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may

require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.

Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of

tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA

is going to be coadministered with another drug known to be an inhibitor of P450 2D6.

Monoamine oxidase inhibitors – see CONTRAINDICATIONS section. Guanethidine or similarly

acting compounds; thyroid medication; alcohol, barbiturates and other CNS depressants; and disulfiram

– see WARNINGS section.

When amitriptyline is given with anticholinergic agents or sympathomimetic drugs, including

epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are

required.

Hyperpyrexia has been reported when amitriptyline is administered with anticholinergic agents or with

neuroleptic drugs, particularly during hot weather.

Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-

type drugs.

Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby

delaying elimination and increasing steady-state concentrations of these drugs. Clinically significant

effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.

Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects,

particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.

Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and

cimetidine may decrease the plasma levels and efficacy of the antidepressants.

Caution is advised if patients receive large doses of ethchlorvynol concurrently. Transient delirium has

been reported in patients who were treated with one gram of ethchlorvynol and 75 to 150 mg of

amitriptyline hydrochloride.

Geriatric Use

Clinical experience has not identified differences in responses between elderly and younger patients. In

general, dose selection for an elderly patient should be cautious, usually starting at the low end of the

dosing range, reflecting the greater frequency of decreased hepatic function, concomitant disease and

other drug therapy in elderly patients.

Geriatric patients are particularly sensitive to the anticholinergic side effects of tricyclic

antidepressants including amitriptyline hydrochloride. Peripheral anticholinergic effects include

tachycardia, urinary retention, constipation, dry mouth, blurred vision, and exacerbation of narrow-angle

glaucoma. Central nervous system anticholinergic effects include cognitive impairment, psychomotor

slowing, confusion, sedation, and delirium. Elderly patients taking amitriptyline hydrochloride may be at

increased risk for falls. Elderly patients should be started on low doses of amitriptyline hydrochloride

and observed closely (see DOSAGE AND ADMINISTRATION).

Pediatric Use

Safety and effectiveness in the pediatric population have not been established (see BOX WARNING

and WARNINGS: Clinical Worsening and Suicide Risk). Anyone considering the use of amitriptyline

in a child or adolescent must balance the potential risks with the clinical need.

ADVERSE REACTIONS

Within each category the following adverse reactions are listed in order of decreasing severity.

Included in the listing are a few adverse reactions which have not been reported with this specific drug.

However, pharmacological similarities among the tricyclic antidepressant drugs require that each of the

reactions be considered when amitriptyline is administered.

Cardiovascular: Myocardial infarction; stroke; nonspecific ECG changes and changes in AV

conduction; heart block; arrhythmias; hypotension, particularly orthostatic hypotension; syncope;

hypertension; tachycardia; palpitation.

CNS and Neuromuscular: Coma; seizures; hallucinations; delusions; confusional states; disorientation;

incoordination; ataxia; tremors; peripheral neuropathy; numbness, tingling, and paresthesias of the

extremities; extrapyramidal symptoms including abnormal involuntary movements and tardive dyskinesia;

dysarthria; disturbed concentration; excitement; anxiety; insomnia; restlessness; nightmares; drowsiness;

dizziness; weakness; fatigue; headache; syndrome of inappropriate ADH (antidiuretic hormone)

secretion; tinnitus; alteration in EEG patterns.

Anticholinergic: Paralytic ileus; hyperpyrexia; urinary retention; dilatation of the urinary tract;

constipation; blurred vision, disturbance of accommodation, increased ocular pressure, mydriasis; dry

mouth.

Allergic: Skin rash; urticaria; photosensitization; edema of face and tongue.

Hematologic: Bone marrow depression including agranulocytosis, leukopenia, thrombocytopenia;

purpura; eosinophilia.

Gastrointestinal: Rarely hepatitis (including altered liver function and jaundice); nausea; epigastric

distress; vomiting; anorexia; stomatitis; peculiar taste; diarrhea; parotid swelling; black tongue.

Endocrine: Testicular swelling and gynecomastia in the male; breast enlargement and galactorrhea in

the female; increased or decreased libido; impotence; elevation and lowering of blood sugar levels.

Other: Alopecia; edema; weight gain or loss; urinary frequency; increased perspiration.

Withdrawal Symptoms

After prolonged administration, abrupt cessation of treatment may produce nausea, headache, and

malaise. Gradual dosage reduction has been reported to produce, within two weeks, transient symptoms

including irritability, restlessness, and dream and sleep disturbance.

These symptoms are not indicative of addiction. Rare instances have been reported of mania or

hypomania occurring within 2 to 7 days following cessation of chronic therapy with tricyclic

antidepressants.

Causal Relationship Unknown

Other reactions, reported under circumstances where a causal relationship could not be established, are

listed to serve as alerting information to physicians:

Body as a Whole: Lupus-like syndrome (migratory arthritis, positive ANA and rheumatoid factor).

Digestive: Hepatic failure, ageusia.

Postmarketing Adverse Events

A syndrome resembling neuroleptic malignant syndrome (NMS) has been very rarely reported after

starting or increasing the dose of amitriptyline hydrochloride, with and without concomitant medications

known to cause NMS. Symptoms have included muscle rigidity, fever, mental status changes,

diaphoresis, tachycardia, and tremor.

Very rare cases of serotonin syndrome (SS) have been reported with amitriptyline hydrochloride in

combination with other drugs that have a recognized association with SS.

OVERDOSAGE

Deaths may occur from overdosage with this class of drugs. Multiple drug ingestion (including

alcohol) is common in deliberate tricyclic antidepressant overdose. As the management is complex and

changing, it is recommended that the physician contact a poison control center for current information on

treatment. Signs and symptoms of toxicity develop rapidly after tricyclic antidepressant overdose,

therefore, hospital monitoring is required as soon as possible.

Manifes tations

Critical manifestations of overdose include: cardiac dysrhythmias, severe hypotension, convulsions, and

CNS depression, including coma. Changes in the electrocardiogram, particularly in, QRS axis or width,

are clinically significant indicators of tricyclic antidepressant toxicity. In addition, a rightward axis shift

in the terminal QRS complex together with a prolonged QT interval and sinus tachycardia are specific

and sensitive indicators of first generation tricyclic overdose. The absence of these findings is not

exclusionary. Prolonged PR interval, ST-T wave changes, ventricular tachycardia and fibrillation may

also occur.

Other signs of overdose may include: impaired myocardial contractility, confusion, disturbed

concentration, transient visual hallucinations, dilated pupils, disorders of ocular motility, agitation,

hyperactive reflexes, polyradiculoneuropathy, stupor, drowsiness, muscle rigidity, vomiting,

hypothermia, hyperpyrexia, or any of the symptoms listed under ADVERSE REACTIONS.

Management

General

Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an

intravenous line and initiate gastric decontamination. A minimum of six hours of observation with

cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac

dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time

during the period, extended monitoring is required. There are case reports of patients succumbing to

fatal dysrhythmias late after overdose; these patients had clinical evidence of significant poisoning

prior to death and most received inadequate gastrointestinal decontamination. Monitoring of plasma drug

levels should not guide management of the patient.

Gastrointestinal Decontamination

All patients suspected of tricyclic antidepressant overdose should receive gastrointestinal

decontamination. This should include, large volume gastric lavage followed by activated charcoal. If

consciousness is impaired, the airway should be secured prior to lavage. EMESIS IS

CONTRAINDICATED.

Cardiovascular

A maximal limb-lead QRS duration of ≥0.10 seconds may be the best indication of the severity of the

overdose. Intravenous sodium bicarbonate should be used to maintain the serum pH in the range of 7.45

to 7.55. If the pH response is inadequate, hyperventilation may also be used. Concomitant use of

hyperventilation and sodium bicarbonate should be done with extreme caution, with frequent pH

monitoring. A pH >7.60 or a pCO <20 mm Hg is undesirable. Dysrhythmias unresponsive to sodium

bicarbonate therapy/hyperventilation may respond to lidocaine, bretylium or phenytoin. Type 1 A and 1

C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide, and procainamide).

In rare instances, hemoperfusion may be beneficial in acute refractory cardiovascular instability in

patients with acute toxicity. However, hemodialysis, peritoneal dialysis, exchange transfusions, and

forced diuresis generally have been reported as ineffective in tricyclic antidepressant poisoning.

CNS

In patients with CNS depression, early intubation is advised because of the potential for abrupt

deterioration. Seizures should be controlled with benzodiazepines, or if these are ineffective, other

anticonvulsants (e.g., phenobarbital, phenytoin).

Physostigmine is not recommended except to treat life-threatening symptoms that have been

unresponsive to other therapies, and then only in consultation with a poison control center.

Psychiatric Follow-up

Since overdosage is often deliberate, patients may attempt suicide by other means during the recovery

phase. Psychiatric referral may be appropriate.

Pediatric Management

The principles of management of pediatric and adult overdosages are similar. It is strongly

recommended that the physician contact the local poison control center for specific pediatric treatment.

DOSAGE AND ADMINISTRATION

Oral Dosage

Dosage should be initiated at a low level and increased gradually, noting carefully the clinical response

and any evidence of intolerance.

Initial Dosage for Adults

For outpatients 75 mg of amitriptyline HCl a day in divided doses is usually satisfactory. If necessary,

this may be increased to a total of 150 mg per day. Increases are made preferably in the late afternoon

and/or bedtime doses. A sedative effect may be apparent before the antidepressant effect is noted, but an

adequate therapeutic effect may take as long as 30 days to develop.

An alternate method of initiating therapy in outpatients is to begin with 50 to 100 mg amitriptyline HCl at

bedtime. This may be increased by 25 or 50 mg as necessary in the bedtime dose to a total of 150 mg

per day.

Hospitalized patients may require 100 mg a day initially. This can be increased gradually to 200 mg a

day if necessary. A small number of hospitalized patients may need as much as 300 mg a day.

Adolescent and Elderly Patients

In general, lower dosages are recommended for these patients. Ten mg 3 times a day with 20 mg at

bedtime may be satisfactory in adolescent and elderly patients who do not tolerate higher dosages.

Maintenance

The usual maintenance dosage of amitriptyline HCl is 50 to 100 mg per day. In some patients 40 mg per

day is sufficient. For maintenance therapy the total daily dosage may be given in a single dose

preferably at bedtime. When satisfactory improvement has been reached, dosage should be reduced to

the lowest amount that will maintain relief of symptoms. It is appropriate to continue maintenance therapy

3 months or longer, to lessen the possibility of relapse.

Usage in Pediatric Patients

In view of the lack of experience with the use of this drug in pediatric patients, it is not recommended at

the present time for patients under 12 years of age.

Plasma Levels

Because of the wide variation in the absorption and distribution of tricyclic antidepressants in body

fluids, it is difficult to directly correlate plasma levels and therapeutic effect. However, determination

of plasma levels may be useful in identifying patients who appear to have toxic effects and may have

excessively high levels, or those in whom lack of absorption or noncompliance is suspected. Because

of increased intestinal transit time and decreased hepatic metabolism in elderly patients, plasma levels

are generally higher for a given oral dose of amitriptyline hydrochloride than in younger patients.

Elderly patients should be monitored carefully and quantitative serum levels obtained as clinically

appropriate. Adjustments in dosage should be made according to the patient's clinical response and not

on the basis of plasma levels.

HOW SUPPLIED

Product: 71335-1254

NDC: 71335-1254-0 120 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1254-1 20 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1254-2 30 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1254-3 100 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1254-4 60 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1254-5 50 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1254-6 90 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1254-7 45 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1254-8 28 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1254-9 56 TABLET, FILM COATED in a BOTTLE

Product: 71335-1256

NDC: 71335-1256-1 100 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1256-2 30 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1256-3 60 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1256-4 90 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1256-5 20 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1256-6 28 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1256-7 56 TABLET, FILM COATED in a BOTTLE

NDC: 71335-1256-8 180 TABLET, FILM COATED in a BOTTLE

METABOLISM

Studies in man following oral administration of

C-labeled drug indicated that amitriptyline is rapidly

absorbed and metabolized. Radioactivity of the plasma was practically negligible, although significant

amounts of radioactivity appeared in the urine by 4 to 6 hours and one-half to one-third of the drug was

excreted within 24 hours.

Amitriptyline is metabolized by N-demethylation and bridge hydroxylation in man, rabbit and rat.

Virtually the entire dose is excreted as glucuronide or sulfate conjugate of metabolites, with little

unchanged drug appearing in the urine. Other metabolic pathways may be involved.

REFERENCES

Ayd, F.J., Jr.: Amitriptyline therapy for depressive reactions, Psychosom. 1: 320–325, Nov.–Dec. 1960.

Diamond, S.: Human metabolization of amitriptyline tagged with carbon 14, Curr. Therap. Res.7: 170–

175, Mar. 1965.

Hollister, L.E.; Monitoring Tricyclic Antidepressant Plasma Concentrations. JAMA 1979; 24 1 (23):2530-2533.

Dorfman, W.: Clinical experiences with amitriptyline (A preliminary report), Psychosom. 1: 153–155,

May–June 1960.

Fallette, J.M.; Stasney, C.R.; Mintz, A.A.: Amitriptyline poisoning treated with physostigmine, S. Med. J.

63: 1492–1493, Dec. 1970 (in Soc. Proc.).

Hollister, L.E.; Overall, J.E.; Johnson, M.; Pennington, V.; Katz, G.; Shelton, J.: Controlled comparison

of amitriptyline, imipramine and placebo in hospitalized depressed patients, J. Nerv. and Ment. Dis. 139:

370–375, Oct. 1964.

Hordern, A.; Burt, C.G.; Holt, N.F.: Depressive states. A pharmacotherapeutic study, Springfield, Ill.,

Charles C. Thomas, 1965.

Jenike, M.A.: Treatment of Affective Illness in the Elderly with Drugs and Electroconvulsive Therapy,

J. Geriatr. Psychiatry 1989;22(1).77–112.

Klerman, G.L.; Cole, J.O.: Clinical pharmacology of imipramine and related antidepressant compounds,

Int. J. Psychiat. 3: 267–304, Apr. 1976.

Liu, B.; Anderson, C.; Mittman, N. et al: Use of selective serotonin-reuptake inhibitors or tricyclic

antidepressants and risk of hip fractures in elderly people. Lancet 1998; 351 (9112):1303–1307.

McConaghy, N.; Joffe, A.D.; Kingston, W.R.; Stevenson, H.G.; Atkinson, I.; Cole, E.; Fennessy, L.A.;

Correlation of clinical features of depressed outpatients with response to amitriptyline and

protriptyline, Brit. J. Psychiat. 114: 103–106, Jan. 1968.

McDonald, I.M.; Perkins, M.; Marjerrison, G.; Podilsky, M.: A controlled comparison of amitriptyline

and electroconvulsive therapy in the treatment of depression, Amer. J. Psychiat. 122: 1427–1431. June

1966 (in Brief Communications).

Slovis, T.; Ott, J.; Teitelbaum, D.; Lipscomb, W.: Physostigmine therapy in acute tricyclic

antidepressant poisoning. Clin. Toxicol. 4: 451–459, Sept. 1971.

Symposium on depression with special studies of a new antidepressant, amitriptyline, Dis. Nerv. Syst. 22:

5–56, May 1961 (Sect. 2).

Distributed by:

Sun Pharmaceutical Industries, Inc.

Cranbury, NJ 08512

Rev 04, February 2018

MEDICATION GUIDE

Amitriptyline Hydrochloride Tablets, USP

(am'' i trip' ti leen hye'' droe klor' ide)

Antidepressant Medicines, Depression and other Serious Mental Illnesses, and Suicidal

Thoughts or Actions

Read the Medication Guide that comes with you or your family member's antidepressant medicine. This

Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines.

Talk to your, or your family member's, healthcare provider about:

What is the most important information I should know about antidepressant medicines,

depression and other serious mental illnesses, and suicidal thoughts or actions?

all risks and benefits of treatment with antidepressant medicines

all treatment choices for depression or other serious mental illness

What else do I need to know about antidepressant medicines?

Antidepressant medicines may increase suicidal thoughts or actions in some children,

teenagers, and young adults within the first few months of treatment.

Depression and other serious mental illnesses are the most important causes of suicidal

thoughts and actions. Some people may have a particularly high risk of having suicidal

thoughts or actions. These include people who have (or have a family history of) bipolar illness

(also called manic-depressive illness) or suicidal thoughts or actions.

How can I watch for and try to prevent suicidal thoughts and actions in myself or a family

member?

Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts,

or feelings. This is very important when an antidepressant medicine is started or when the

dose is changed.

Call the healthcare provider right away to report new or sudden changes in mood, behavior,

thoughts, or feelings.

Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare

provider between visits as needed, especially if you have concerns about symptoms.

Call a healthcare provider right away if you or your family member has any of the following

symptoms, especially if they are new, worse, or worry you:

thoughts about suicide or dying

attempts to commit suicide

new or worse depression

new or worse anxiety

feeling very agitated or restless

panic attacks

trouble sleeping (insomnia)

new or worse irritability

acting aggressive, being angry, or violent

acting on dangerous impulses

an extreme increase in activity and talking (mania)

other unusual changes in behavior or mood

Visual problems: eye pain, changes in vision, swelling or redness in or around the eye

Never stop an antidepressant medicine without first talking to a healthcare provider.

Stopping an antidepressant medicine suddenly can cause other symptoms.

Visual problems: Only some people are at risk for these problems. You may want to undergo an

eye examination to see if you are at risk and receive preventative treatment if you are.

Antidepressants are medicines used to treat depression and other illnesses. It is important to

discuss all the risks of treating depression and also the risks of not treating it. Patients and their

families or other caregivers should discuss all treatment choices with the healthcare provider, not

just the use of antidepressants.

Antidepressant medicines have other side effects. Talk to the healthcare provider about the

side effects of the medicine prescribed for you or your family member.

Antidepressant medicines can interact with other medicines. Know all of the medicines that

you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do

not start new medicines without first checking with your healthcare provider.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-

800-FDA-1088.

This Medication Guide has been approved by the U.S. Food and Drug Administration for all

antidepressants.

Distributed by:

Sun Pharmaceutical Industries, Inc.

Cranbury, NJ 08512

Rev 04, February 2018

Amitriptyline HCL 25mg Tablet

Amitriptyline HCL 50mg Tablet

AMITRIPTYLINE HYDROCHLORIDE

amitriptyline hydrochloride tablet, film coated

Not all antidepressant medicines prescribed for children are FDA approved for use in

children. Talk to your child's healthcare provider for more information.

Product Information

Product T ype

HUMAN PRESCRIPTION DRUG

Ite m Code (Source )

NDC:71335-1254(NDC:576 6 4-6 8 8 )

Route of Administration

ORAL

Active Ingredient/Active Moiety

Ingredient Name

Basis of Strength

Stre ng th

AMITRIPTYLINE HYDRO CHLO RIDE (UNII: 26 LUD4JO9 K) (AMITRIPTYLINE -

UNII:18 0 6 D8 D52K)

AMITRIPTYLINE

HYDROCHLORIDE

25 mg

Inactive Ingredients

Ingredient Name

Stre ng th

silico n dio xide (UNII: ETJ7Z6 XBU4)

cro sca rmello se so dium (UNII: M28 OL1HH48 )

la cto se mo no hydra te (UNII: EWQ57Q8 I5X)

ma g nesium stea ra te (UNII: 70 0 9 7M6 I30 )

MICRO CRYSTALLINE CELLULO SE (UNII: OP1R32D6 1U)

PO LYETHYLENE GLYCO L, UNSPECIFIED (UNII: 3WJQ0 SDW1A)

tita nium dio xide (UNII: 15FIX9 V2JP)

D&C Yello w No . 10 (UNII: 35SW5USQ3G)

Aluminum O xide (UNII: LMI26 O6 9 33)

FD&C Blue No . 1 (UNII: H3R47K3TBD)

FD&C Red No . 4 0 (UNII: WZB9 127XOA)

PO LYVINYL ALCO HO L, UNSPECIFIED (UNII: 532B59 J9 9 0 )

TALC (UNII: 7SEV7J4R1U)

Product Characteristics

Color

GREEN

S core

no sco re

S hap e

ROUND

S iz e

6 mm

Flavor

Imprint Code

MP;25

Contains

Packag ing

#

Item Code

Package Description

Marketing Start Date

Marketing End Date

1

NDC:71335-1254-0

120 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

2

NDC:71335-1254-1

20 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

3

NDC:71335-1254-2

30 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

4

NDC:71335-1254-3

10 0 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

5

NDC:71335-1254-4

6 0 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

6

NDC:71335-1254-5

50 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

7

NDC:71335-1254-6

9 0 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

8

NDC:71335-1254-7

45 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

9

NDC:71335-1254-8

28 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

10

NDC:71335-1254-9

56 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

Marketing Information

Marke ting Cate gory

Application Numbe r or Monograph Citation

Marke ting Start Date

Marke ting End Date

ANDA

ANDA0 8 9 39 9

0 7/14/19 8 7

AMITRIPTYLINE HYDROCHLORIDE

amitriptyline hydrochloride tablet, film coated

Product Information

Product T ype

HUMAN PRESCRIPTION DRUG

Ite m Code (Source )

NDC:71335-1256 (NDC:576 6 4-6 8 9 )

Route of Administration

ORAL

Active Ingredient/Active Moiety

Ingredient Name

Basis of Strength

Stre ng th

AMITRIPTYLINE HYDRO CHLO RIDE (UNII: 26 LUD4JO9 K) (AMITRIPTYLINE -

UNII:18 0 6 D8 D52K)

AMITRIPTYLINE

HYDROCHLORIDE

50 mg

Inactive Ingredients

Ingredient Name

Stre ng th

silico n dio xide (UNII: ETJ7Z6 XBU4)

cro sca rmello se so dium (UNII: M28 OL1HH48 )

la cto se mo no hydra te (UNII: EWQ57Q8 I5X)

ma g nesium stea ra te (UNII: 70 0 9 7M6 I30 )

MICRO CRYSTALLINE CELLULO SE (UNII: OP1R32D6 1U)

PO LYETHYLENE GLYCO L, UNSPECIFIED (UNII: 3WJQ0 SDW1A)

tita nium dio xide (UNII: 15FIX9 V2JP)

FD&C Red No . 4 0 (UNII: WZB9 127XOA)

Aluminum O xide (UNII: LMI26 O6 9 33)

FD&C Blue No . 2 (UNII: L0 6 K8 R7DQK)

PO LYVINYL ALCO HO L, UNSPECIFIED (UNII: 532B59 J9 9 0 )

TALC (UNII: 7SEV7J4R1U)

FD&C YELLO W NO . 5 (UNII: I753WB2F1M)

Product Characteristics

Color

BROWN

S core

no sco re

S hap e

ROUND

S iz e

8 mm

Flavor

Imprint Code

MP;26

Contains

Packag ing

#

Item Code

Package Description

Marketing Start Date

Marketing End Date

1

NDC:71335-1256 -1

10 0 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

2

NDC:71335-1256 -2

30 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

Bryant Ranch Prepack

2

NDC:71335-1256 -2

30 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

3

NDC:71335-1256 -3

6 0 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

4

NDC:71335-1256 -4

9 0 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

5

NDC:71335-1256 -5

20 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

6

NDC:71335-1256 -6

28 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

7

NDC:71335-1256 -7

56 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

8

NDC:71335-1256 -8

18 0 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 6 /27/20 19

Marketing Information

Marke ting Cate gory

Application Numbe r or Monograph Citation

Marke ting Start Date

Marke ting End Date

ANDA

ANDA0 8 9 39 9

0 7/14/19 8 7

Labeler -

Bryant Ranch Prepack (171714327)

Establishment

Name

Ad d re s s

ID/FEI

Busine ss Ope rations

Bryant Ranch Prepack

171714327

REPACK(71335-1254, 71335-1256 ) , RELABEL(71335-1254, 71335-1256 )

Revised: 8/2019

Similar products

Search alerts related to this product

View documents history

Share this information